Skip to main content
NewslettersWatchlist

Medexus Pharmaceuticals Inc(MDP-T)
TSX

Today's Change
Real-Time Last Update
Day Low2.12
Day High2.16
Open:2.16
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Newsfile
Medexus and pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for Trecondyv (treosulfan for injection) in Canada
Newsfile
Medexus Announces Strong Fiscal Q2 2025 Results
Newsfile
Medexus Schedules Second Fiscal Quarter 2025 Conference Call
AI-generated - The Globe and Mail
Medexus Pharma: Top 10 Undervalued Drug Manufacturers Industry Stocks (MDP)
Newsfile
Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors
Newsfile
Medexus Provides Update on Treosulfan NDA Review Process and Extended PDUFA Goal Date
AI-generated - The Globe and Mail
Medexus Pharma: Top 10 Undervalued Drug Manufacturers Industry Stocks (MDP)
AI-generated - The Globe and Mail
Medexus Pharma:Stocks Analysts Recently Upgraded on TSX (MDP)
Newsfile
Medexus Announces Strong Fiscal Q1 2025 Results
Newsfile
Medexus Schedules First Fiscal Quarter 2025 Conference Call
Newsfile
Medexus Generates Record Revenue of US$113.1 Million in Fiscal Year 2024
Newsfile
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2024 Conference Call
AI-generated - The Globe and Mail
Medexus Pharma: Top 10 Undervalued Drug Manufacturers Industry Stocks (MDP)
AllPennyStocks.com
News of NDA Resubmission Is Sending Shares of this Pharma Firm Higher
Newsfile
FDA Accepts for Review Treosulfan NDA Resubmission
Newsfile
Medexus Concludes Metoject Litigation, Patent No Longer in Effect in Canada
Newsfile
Medexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
AI-generated - The Globe and Mail
Medexus Pharma: Bottom 25 Performing Stocks Year-to-Date on TSX (MDP)
Newsfile
FDA Approves Medexus's Supplemental Biologics License Application for IXINITY(R) to Treat Hemophilia B in Pediatric Patients
Newsfile
Medexus Announces Fiscal Q3 2024 Results
Newsfile
Medexus Schedules Third Fiscal Quarter 2024 Conference Call
Newsfile
Health Canada Accepts for Review Medexus's New Drug Submission for Topical Terbinafine

Profile

Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.